Zecotek Photonics 1,22€
Zecotek Medical name change to Zecotek Photonics.
2007-11-23 16:36 ET - New Listing
Pursuant to a resolution passed by directors on Oct. 3, 2007, Zecotek Medical Systems Inc. has changed its name as follows. There is no consolidation of capital.
Effective at the opening on Monday, Nov. 26, 2007, the common shares of Zecotek Photonics Inc. will commence trading on the TSX Venture Exchange, and the common shares of Zecotek Medical Systems will be delisted. The company is classified as a medical research and development company.
Capitalization: Unlimited shares with no par value, of which 41,422,607 shares are issued and outstanding
Escrow: 12,724,378 shares
Transfer agent: Computershare Trust Company of Canada
Symbol: ZMS (unchanged)
New Cusip No.: 98921P 10 4
Optionen
| Boardmail an "petruss" |
Wertpapier: Zecotek Photonics |
Optionen
| Boardmail an "petruss" |
Wertpapier: Zecotek Photonics |
November 26, 2007
Zecotek Announces Appointments to Scientific Advisory Board
Vancouver, November 26, 2007 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), formerly Zecotek Medical Systems Inc., today announced it has appointed Dr. K.A. Abraham and Dr. Teoh Tiong Ann to its Advisory Board.
“We are very fortunate to welcome both Dr. Abraham and Dr. Teoh to our Advisory Board,” said Dr. A. F. Zerrouk, Chairman, President, and CEO of Zecotek. “Both Dr. Abraham and Dr. Teoh are recognized experts in their respective fields and we expect them to make significant contributions to the design and development of our medical imaging products, including our PET/MRI , our Optical Coherent Tomography device as well as a range of medical lasers used both in treatment and diagnostics.”
Dr. K.A. Abraham is a Consultant E.N.T. Surgeon who has been in private practice since 1984. He has held the position of Deputy Head at the E.N.T. Department of the Singapore General Hospital, and later was the first Head of the E.N.T. Department at Tan Tock Seng Hospital. He helped establish the E.N.T. Department at the National University Hospital and was a visiting Consultant at the University until 2002. Dr. K.A. Abraham received his MBBS from the University of Singapore (1969). He is a Fellow of The Royal College of Surgeons, Edinburgh (1973), a member of the Academy of Medicine, Singapore and is a past President of the Society of Otolaryngology in Singapore.
Dr. Teoh Tiong Ann is a recognized expert in Laparoscopic (keyhole) surgery and is currently the Consultant Colorectal Surgeon and General Surgeon at the Mount Elizabeth Medical Centre in Singapore. He received his MBBS (1985) and Master of Medicine (Surgery)(1990) from the National University of Singapore under the auspices of a Singapore Government Public Services Commission Merit Scholarship. He is a Fellow of the Royal College of Surgeons (Edinburgh)(1990) and the Academy of Medicine, Singapore (1994). Dr. Teoh is a Founding Member of Endoscopic & Laparoscopic Surgeons of Asia and also a Founding member of the Society of Colorectal Surgeons of Singapore. He is also a Member of the American Society of Colon & Rectal Surgeons and was previously a member of the Technologies Committee of this American Society.
Zecotek has granted 160,000 stock options, to the new members of the Advisory Board, with an exercise price of $1.79 and expiration date of November 26, 2012. The stock options are subject to regulatory approval.
About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, USA, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For additional information please contact:
Zecotek Photonics Inc.
MICHAEL MINDER, CFO; VP Corporate Development, T: (604) 827-5203
Caliber Capital Partners
TIM MCNULTY, T: (778) 327-6678, E: ir@zecotek.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
BÖRSENPLÄTZE
Symbol Börse Name Uhrzeit Kurs Veränd. % Veränd. Volumen Intraday
A0JKHL Frankfurt§ZECOTEK MED SYS 22 Nov 1,25 € Down 0,01 -0,79% 71.791
A0JKHL XETRA§ZECOTEK MED SYS 21 Nov 1,32 € Down 0,02 -1,49% 19.470
A0JKHL Stuttgart§ZECOTEK MED SYS 22 Nov 1,27 € Up 0,01 +0,79% 17.477
A0JKHL München§ZECOTEK MED SYS 22 Nov 1,28 € Up 0,01 +0,79% 16.000
CA9892131033Berlin-Bremen§ZECOTEK PHOTONICS 26 Nov 1,25 € Up 0,06 +5,04% 11.400
NACHRICHTEN §
Optionen
| Boardmail an "18prozent" |
Wertpapier: Zecotek Photonics |
könnte diese Aktie dann auch zur Zeit nicht verkaufen oder ??
will ich aber auch nicht :-)
grüße
Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of $2.10 per common share for a period of 24 months after the date the private placement closes.
Pursuant to the financing, the Company will pay to Loewen 7% of the gross proceeds of the sale of the Units and issue non-transferable agent’s warrants to purchase common shares equal in number to 7% of the units sold under the private placement. Each agent's warrant will entitle the holder to purchase one Share at the issue price of $1.60, for a period of 24 months following the Closing of the Private Placement. Closing of the private placement is scheduled to take place on or about December 20, 2007, and is subject to the completion of subscription agreements with the investors and the approval of the TSX Venture Exchange. The common shares and warrants issued pursuant to the private placement will be subject to a four-month hold period.
Net proceeds from the funds raised will be used for working capital purposes and for ongoing projects presently underway at its operating facilities in Singapore, Malaysia and Vancouver: finalizing the commercial production of the Zecotek’s solid-state MAPD photo-detector, addressing growing requests for the Company’s fiber and solid-state lasers, and initiating commercial scale production of the Company’s high performance RFO vanadate laser crystals and establishing a strategic manufacturing and distribution partnership for the Company’s 3D display system.
Optionen
| Boardmail an "petruss" |
Wertpapier: Zecotek Photonics |
2007-11-29 11:32 ET - News Release
Mr. Michael Minder reports
ZECOTEK ANNOUNCES $3 MILLION PRIVATE PLACEMENT
Zecotek Photonics Inc., formerly Zecotek Medical Systems Inc., has engaged Loewen, Ondaatje, McCutcheon Ltd. to conduct a brokered private placement to raise, on a best-efforts agency basis, up to $3-million through issue of up to 1,875,000 units of the company at a price of $1.60 per unit.
Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of $2.10 per common share for a period of 24 months after the date the private placement closes.
Pursuant to the financing, the company will pay to Loewen 7 per cent of the gross proceeds of the sale of the units and issue non-transferable agent's warrants to purchase common shares equal in number to 7 per cent of the units sold under the private placement. Each agent's warrant will entitle the holder to purchase one share at the issue price of $1.60 for a period of 24 months following the closing of the private placement. Closing of the private placement is scheduled to take place on or about Dec. 20, 2007, and is subject to the completion of subscription agreements with the investors and the approval of the TSX Venture Exchange. The common shares and warrants issued pursuant to the private placement will be subject to a four-month hold period.
Net proceeds from the funds raised will be used for working capital purposes, and for continuing projects presently under way at the company's operating facilities in Singapore, Malaysia and Vancouver, including:
* Finalizing the commercial production of the Zecotek's solid state MAPD photo detector;
* Addressing growing requests for the company's fibre and solid state lasers;
* Initiating commercial-scale production of the company's high-performance RFO vanadate laser crystals;
* Establishing a strategic manufacturing and distribution partnership for the company's 3-D display system.
We seek Safe Harbor.
Optionen
| Boardmail an "petruss" |
Wertpapier: Zecotek Photonics |
Optionen
| Boardmail an "petruss" |
Wertpapier: Zecotek Photonics |
December 03, 2007
Zecotek Demonstrates 32” 3D Display to Industry; Engages Insight Media to Advise on Market Entry
Vancouver, BC, December 3, 2007 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), formerly Zecotek Medical Systems Inc., today announced it has initiated demonstrations of the 32” commercial prototype of its proprietary Real-Time 3D2D Display System©, the first 3D display offering multiple viewers true volumetric visualization while exhibiting depth and parallax over a wide viewing angle. The demonstrations have started and are scheduled over the next several weeks at the Company’s Vancouver laboratories for a select group of representatives of potential industry partners.
Zecotek also announced that it has engaged Insight Media, a leading publishing and consulting firm focused on the display industry, to provide advice and guidance on a market entry strategy for the display system.
“We have reached a critical milestone in the commercialization of our 3D display technology with the 32” prototype,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “Our system delivers true 3D over a wide viewing angle, in high resolution colour and establishes a new benchmark in the 3D industry. Our next step is to select strategic partners in the manufacture and distribution of what we feel is a new and potentially revolutionary display technology and we look forward to working with Insight Media to leverage our market position.”
Zecotek’s Real-Time 3D2D Display System is a novel, proprietary display system for the visualization of images and data. Based on the autostereoscopic principle, but with substantial patent pending innovation, it represents a new generation of 3D displays. The 32” commercial prototype is designed for multi-user, multi-view with freedom of movement. It delivers full colour, high resolution images in both 3D and 2D mode (greater than 1024x768), has superior image dynamic range in 2D mode and the system is compatible with existing applications. Anteryon BV of the Netherlands produced the key screen component of the 3D display.
“We are very impressed with the high resolution, wide viewing angle and multi-viewer features of Zecotek’s 3D display system,” said Geoff Bertenshaw, Chief Executive Officer of Anteryon. “We are pleased to contribute to the production of the first commercial prototype in what we see as a truly breakthrough product. We look forward to building on our strategic partnership with Zecotek.”
Was war ich gestern gespannt auf die Präsentation des 3D Displays in den Räumen von Zecotek Photonics in Vancouver.
Ich will nicht lange um den heißen Brei herumreden! Mir sind fast die Augen aus dem Kopf gefallen, so gewaltig war der 3D Effekt.
Ich habe einen kreisenden Hüftknochen gesehen, einen sich drehenden Echsenkopf, ein Männchen bei einer Werkbank und ein Blumengesteck. Der 3D Effekt war so real und klar, dass mit mir anwesende Personen versuchten die Dinge zu greifen, die sich hier augenscheinlich aus dem Bildschirm herausreckten. Aber die Bilder drehen sich nicht nur nach vorne heraus, nein, der Effekt geht auch in die Tiefe.
Ein statischer Hüftknochen konnte durch die Veränderung des Blickwinkels auch von der Seite betrachtet werden.
Aber was zählt schon meine Meinung...
Viel wichtiger ist die Meinung des anwesenden Medienspezialisten Arthur Berman Ph.D. von Insight Media! Er meinte nur kurz und knapp, dass er alles im 3D Display Bereich schon gesehen hat und dieses Gerät alles um Längen schlägt.
Nach dieser gelungen Präsentation ist Zecotek kein günstiger Kauf sondern einfach nur spottbillig! Allein dieses 3D Display würde schon eine wesentlich höhere Marktkapitalisierung rechtfertigen! Aber es gibt ja auch noch die Laser und die Pet Kristalle und die Photonenzähler und, und, und...